# Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

> **NCT00577577** · PHASE2 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 69 (actual)

## Conditions studied

- Myotonic Dystrophy Type 1

## Interventions

- **DRUG:** rhIGF-I/rhIGFBP-3
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00577577
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-12-29
- **Final completion:** 2008-12-29
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577577, "Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00577577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*